Trial
NCT06881823
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Prostate Cancer
Intervention
AAA602
Why stopped
The radioligands to be evaluated showed acceptable safety but limited benefit in metastatic prostate cancer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-29